Anthracyclines in the treatment of patients with early breast cancer
Author:
Funder
Gilead Sciences
Università degli Studi di Padova
GlaxoSmithKline
Novartis
Servier
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference51 articles.
1. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials;Peto;Lancet,2012
2. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735;Jones;J Clin Oncol,2009
3. Anthracyclines in early breast cancer: the ABC trials - USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology);Blum;J Clin Oncol,2017
4. Taxane & cyclophosphamide vs anthracycline & taxane-based chemotherapy as adjuvant treatment for breast cancer: a pooled analysis of randomized controlled trials by the Hellenic Academy of Oncology;Ntellas;Oncotarget,2019
5. Braybrooke J, Bradley R, Gray R, et al. Taxane with anthracycline versus taxane without anthracycline: an individual patient-level meta-analysis of 16,500 women with early-stage breast cancer in 13 randomised trials. Cancer Res. 2022;82(4_suppl):GS2-06.
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Neutrophil Biomarkers Can Predict Cardiotoxicity of Anthracyclines in Breast Cancer;International Journal of Molecular Sciences;2024-09-09
2. The relationship between body composition and left ventricular performance in women with breast, lymphoma, or sarcoma cancer;Cardio-Oncology;2024-06-06
3. Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD);ESMO Open;2024-01
4. A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer;Clinical Cancer Research;2023-07-07
5. Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer;Cancers;2022-12-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3